Format

Send to

Choose Destination
Epigenetics. 2014 Sep;9(9):1252-60. doi: 10.4161/epi.29941. Epub 2014 Jul 31.

RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia.

Author information

1
Division of Epigenomics and Cancer Risk Factors (C010); German Cancer Research Center; Heidelberg, Germany.
2
Division of Pediatric Hematology-Oncology; University Medical Center; Freiburg, Germany.
3
Division of Biostatistics; German Cancer Research Center; Heidelberg, Germany.
4
St. Anna Children's Hospital and Children's Cancer Research Institute; Department of Pediatrics; Medical University of Vienna; Vienna, Austria.
5
Dept. of Pediatric Hematology-Oncology; Ghent University Hospital; Ghent, Belgium.
6
Dept. of Pediatric Hematology and Oncology; 2nd Faculty of Medicine; Charles University and University Hospital Motol, Praha; Czech Pediatric Hematology Working Group (CPH); Prague, Czech Republic.
7
Pediatric Hematology-Oncology; Fondazione IRCCS;Policlinico San Matteo; Pavia, Italy.
8
Department of Pediatrics; Aarhus University Hospital Skejby; Aarhus, Denmark.
9
Division of Hematology; University Children's Hospital; Zurich, Switzerland.
10
Department of Pediatric Oncology-Hematology; Erasmus Medical Center; Rotterdam, The Netherlands; Dutch Children's Oncology Group; The Hague, Netherlands.
11
Department of Pediatric Hematology-Oncology; IRCCS Ospedale Bambino Gesu; Rome, Italy; University of Pavia; Pavia, Italy.
12
The German Cancer Consortium; Heidelberg, Germany; Division of Pediatric Hematology-Oncology; University Medical Center; Freiburg, Germany.
13
Division of Epigenomics and Cancer Risk Factors (C010); German Cancer Research Center; Heidelberg, Germany; The German Cancer Consortium; Heidelberg, Germany.

Abstract

Aberrant DNA methylation at specific genetic loci is a key molecular feature of juvenile myelomonocytic leukemia (JMML) with poor prognosis. Using quantitative high-resolution mass spectrometry, we identified RASA4 isoform 2, which maps to chromosome 7 and encodes a member of the GAP1 family of GTPase-activating proteins for small G proteins, as a recurrent target of isoform-specific DNA hypermethylation in JMML (51% of 125 patients analyzed). RASA4 isoform 2 promoter methylation correlated with clinical parameters predicting poor prognosis (older age, elevated fetal hemoglobin), with higher risk of relapse after hematopoietic stem cell transplantation, and with PTPN11 mutation. The level of isoform 2 methylation increased in relapsed cases after transplantation. Interestingly, most JMML cases with monosomy 7 exhibited hypermethylation on the remaining RASA4 allele. The results corroborate the significance of epigenetic modifications in the phenotype of aggressive JMML.

KEYWORDS:

JMML; RASA4; epigenetics,juvenile myelomonocytic leukemia

PMID:
25147919
PMCID:
PMC4169017
DOI:
10.4161/epi.29941
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center